inhaler

Photo by the CDC/FDA

The FDA has approved a new indication of Trelegy Ellipta for the treatment of asthma and patients with chronic obstructive pulmonary disease. 

This was based on a supplemental new drug application which showed that Trelegy provided significant improvements in lung function for patients with these conditions. 

Photo by Mikael Häggström, M.D.

The FDA has granted Lupin Ltd approval for their generic version of ProAir, which is used to prevent asthma symptoms and treat episodes of bronchospasm.

Researchers at AstraZeneca have been left scratching their heads as new Phase 3b results for its inhaler, Bevespi Aerosphere, posted disappointing results compared to a rival product, GSK’s Anoro (umeclidinium/vilanterol), in the treatment of moderate to very severe chronic obstructive pulmonary disease (COPD) – results which the company says are inconsistent with previous findings.

Bevespi Aerosphere is a fixed-dose dual bronchodilator which combines the long-acting muscarinic agonist (LAMA) glycopyrronium with the long-acting beta2-agonist (LABA) formoterol fumarate, making it un

Respiratory drug specialist Vectura’s asthma treatment Flutiform was unsuccessful in meeting the primary endpoint in its Phase III trial conducted by European partner Mundipharma.

The inhaler failed to show a “statistically significant” superiority in reducing the yearly degradation of moderate to severe chronic obstructive pulmonary disease (COPD) compared to mono-component LABA treatment.

Boehringer Ingelheim is to spend more than €100 million at its Dortmund site in Germany in order to expand the production capacity of its inhaler product Respimat.

The company says it is creating around 100 new jobs with the move which will see the German pharma giant ratchet up units of Respimat to 44 million per year.